selected subjects (77% Caucasian, 8% African American, 7% Asian, 6% Hispanic, and 2% other) with both immunoassay-and MS-based E2 levels available were included in the analyses.
The European Male Aging Study (EMAS) is a multicenter population-based study of the determinants of male aging. Detailed study design and methodologies of EMAS are described elsewhere (4) .
Briefly, a total of 3369 community-dwelling men aged 40-79 yr were recruited from population registers in eight European centers: Manchester (UK), Leuven (Belgium), Malmö (Sweden), Tartu (Estonia), Łódz´ (Poland), Szeged (Hungary), Florence (Italy), and Santiago de Compostela (Spain).
The men were invited to attend by letter of invitation for an interviewer-assisted questionnaire, assessment of height and weight, several performance measures, and a fasting blood test. Ethical approval for the study was obtained in accordance with local institutional requirements in each center, and participants gave informed consent. A total of 2908 subjects with both immunoassay-and MSbased E2 levels available were included in the analyses.
Serum analyses

Immunoassay E2
MrOS Sweden: Total E2 was measured using a direct radioimmunoassay (RIA) (Orion Diagnostica, Espoo, Finland) with a limit of detection of 1.4 pg/ml. The intraassay coefficients of variation (CVs) are 2.8%, 3.5% and 5.0% at 23.7, 84.7 and 278.2 pg/ml, respectively; the interassay CVs are 5.8%, 8 .1% and 9.7% at 25.6, 70.8 and 490.2 pg/ml, respectively (Supplemental Table 4 ). Only the serum samples from the Gothenburg subcohort were all fasting morning samples whereas the other two subcohorts also included non fasting samples.
EMAS:
Fasting blood samples were assayed for E2 by an electrochemiluminescence immunoassay on the Modular E170 platform (Roche Diagnostics, Mannheim, Germany) with a limit of detection of 5.0 pg/ml. The intraassay CVs are 6.1%, 3.5% and 1.3% at 39.1, 79.6 and 878 pg/ml, respectively; the interassay CVs are 7.0%, 4.5% and 1.9% at 39.1, 79.6 and 878 pg/ml, respectively (Supplemental Table 4 ).
MrOS US:
Baseline fasting morning blood was collected. Serum total E2 was measured with a direct RIA [Beckman Coulter (formerly Diagnostic Systems Laboratories), Brea, CA] with a detection limit of 2.5 pg/ml. The intraassay CVs are 6.5%, 7.6% and 6.9% at 24.9, 40.4 and 92.6 pg/ml, respectively; the interassay CVs are 9.7%, 8.0% and 12.2% at 28.0, 42.3 and 108.7 pg/ml, respectively (Supplemental Table 4 ).
MS E2
In MrOS Sweden and EMAS, the validated GC-MS system at the Laboratory of Molecular Endocrinology and Oncology, Laval University, Québec, Canada (5-8) was used for the analysis of E2 with a limit of detection of 2 pg/ml. The intraassay CVs are 3.5%, 1.2% and 1.4% at 19.9, 199.9 and 299.9 pg/ml, respectively; the interassay CVs are 3.7%, 2.7% and 3.2% at 19.9, 199.9 and 299.9 pg/ml, respectively (Supplemental Table 5 ). Analytes and internal standard were detected using a HP5973 quadrupole mass spectrometer equipped with a chemical ionization source. Serum samples for sex steroid levels in the MrOS Sweden cohort were available for 99% of the subjects in the Gothenburg cohort and 96% of the subjects in the Malmö cohort, while the one ml required for the GC-MS analyses was only available for 68% of the subjects in the Uppsala cohort. These subjects who MrOS US: Serum E2 levels were analyzed using a combined gas chromatographic-negative ionization tandem MS and liquid chromatographic electrospray tandem MS bioanalytical method (Taylor Technology, Princeton, NJ) with a limit of detection of 0.625 pg/ml, as previously described (7, 9) .
The intraassay CVs are 7.2%, 3.0% and 2.8% at 1.9, 25 and 61 pg/ml, respectively; the interassay CVs are 7.9%, 3.7% and 2.7% at 1.9, 25 and 61 pg/ml, respectively (Supplemental Table 5 ).
C-reactive protein (CRP)
Serum levels of high-sensitivity CRP (hsCRP) in the MrOS Sweden cohort were measured by an ultrasensitive immunoturbidimetric assay (Orion Diagnostica, Espoo, Finland) on a Konelab 20 autoanalyzer (Thermo Fisher Scientific) with an interassay CV below 5%.
In EMAS, hsCRP levels were determined using a solid-phase, chemiluminescent immunometric assay [Immulite 2000 hsCRP assay; Siemens Healthcare Diagnostics (formerly Diagnostics Products Corporation), Surrey, UK] with an interassay CV below 3%.
Assessment of bone mineral density (DXA)
MrOS Sweden: Areal bone mineral density (BMD, g/cm 2 ) of the lumbar spine (L1 to L4) and the proximal femur (total region) was assessed using the Lunar Prodigy DXA (n=2004 from the Uppsala and Malmö cohorts; GE Lunar Corp., Madison, WI, USA) or Hologic QDR 4500/A-Delphi (n=1010 from the Göteborg cohort; Hologic, Waltham, MA, USA). The CVs for the aBMD measurements ranged from 0.5% to 3%. To be able to use DXA measurements performed with equipment from two different manufacturers, a standardized BMD was calculated, as previously described (1). The analyses were also adjusted for study center.
EMAS: aBMD at the lumbar spine (L1 to L4) and the proximal femur (total region) was measured using DXA (QDR 4500 Discovery, Hologic, Inc., Bedford, MA, USA) in two centers (Manchester and Leuven, n=750). The precision errors of these measurements in Leuven were 0.57% and 0.56% at the lumbar spine and total femur region respectively. In Manchester, these precision errors were 0.97% and 0.97% respectively. Both devices were cross-calibrated with the European Spine Phantom.
Assessment of ankle-brachial index
Ankle-brachial index in MrOS Sweden was measured as described previously (10) . Briefly, with a standard mercury sphygmomanometer and a Doppler probe, we conducted duplicate measures of supine blood pressure in the right arm and both ankles after subjects rested in a quiet room for at least 10 min. The study coordinator placed appropriately sized cuffs over the right upper arm and around each ankle, proximal to the malleolus, rapidly inflated them to 30 mm Hg above the audible systolic pressure, and then slowly deflated them over each artery. A hand-held Doppler (Huntleigh Mini Dopplex Model D900, Huntleigh Healthcare AB, Limhamn, Sweden) recorded the pressure in each artery as the first audible systolic pressure. After performing 2 measurements at each site, we used the mean value of systolic pressure taken first in the right brachial artery and then in the right and left posterior tibial artery. We calculated ABI for each leg by dividing the posterior tibial systolic pressure by the upper extremity pressure and used the lowest ABI. Because ABI >1.40 might represent falsely high values due to incompressible arteries (11), we excluded subjects with ABI>1.40 from analyses including ABI.
Assessment of covariates
In MrOS Sweden, height was measured using a Harpenden stadiometer and weight was measured by an electric scale. In the EMAS study, height and weight were measured using standard, calibrated instruments. In MrOS US, height was measured using a Harpenden stadiometer and weight was measured by a balance beam or digital scale. BMI was calculated in all three cohorts according to the
In the initial screening in the MrOS Sweden cohort, we also used the following variables:
Fasting serum insulin was measured with an immunometric method based on chemiluminescence technology on a ADVIA Centaur (Bayer AB, Solna, Sweden; interassay CV <10%). Fasting plasma glucose was quantitated by an enzymatic method on a Modular (Roche, Gothenburg, Sweden; interassay CV <4%). Serum lipid analysis was performed on a Konelab 20 autoanalyzer (Thermo Electron Corp., Vantaa, Finland). Total cholesterol and triglyceride levels were determined in human fasting serum by fully enzymatic techniques. High density lipoprotein (HDL) was determined after precipitation of apolipoprotein (Apo) B-containing lipoproteins with magnesium sulfate and dextran sulfate. Low-density lipoprotein (LDL) was calculated using Friedewald's formula. ApoB and ApoA1 were determined by immunoprecipitation enhanced by polyethylene glycol at 340 nm. Interassay CVs were less than 5% for all Konelab analyses. We used a standardized questionnaire to gather information about amount of physical activity (12) and smoking (13) . Physical activity was the subject's average total daily walking distance, including both walking as a means of exercise and leisure and as a means of outdoor transportation in activities of daily life.
Supplemental Text (RESULTS)
Assessment of agreement and bias between methods for the analysis of serum E2 in men Serum E2 concentrations were measured in the same individual by both immunoassay and MS for a large number of subjects in all cohorts. The two MS techniques were cross-calibrated using 50 samples from the MrOS US study and displayed a strong correlation (Spearman rank correlation coefficient r S =0.95, P<0.001; mean E2 Québec laboratory 19.8 ± 6.6 pg/ml versus mean E2 Taylor laboratory 21.8 ± 7.7 pg/ml) (Supplemental Fig. 1A and (7) ). Comparing the Québec E2 MS with the Taylor E2 MS, Bland-Altman analysis revealed a mean bias of 1.9 pg/ml for the Taylor E2 MS (Supplemental Fig. 1B) , which proved significantly different (P value for difference from paired sample T-test <0.001). Values are given as mean ± SD; for E2 (estradiol), median, interquartile range, and observed range are also given between brackets. MS = mass spectrometry. # Two subjects had serum E2 levels below the limit of detection. * Twenty-two subjects had serum E2 levels below the limit of detection.
SUPPLEMENTAL TABLE 2.
Detailed study subject characteristics in MrOS Sweden.
MrOS Sweden (n = 2599) n = 2599
Smoking (%) 8.6
Physical activity (km/day) 3.9 ± 3.1
Grip strength (kg) 39.9 ± 7.6
Serum hsCRP (mg/l) 4.7 ± 9.9 (2.1, 1.6-3. Values are given as mean ± SD unless indicated otherwise; for hsCRP (high-sensitivity C-reactive protein), median and interquartile range are also given between brackets. BMD = bone mineral density, ABI = ankle-brachial index.
SUPPLEMENTAL TABLE 3.
Detailed study subject characteristics in EMAS. Values are given as mean ± SD; for hsCRP (high-sensitivity C-reactive protein), median and interquartile range are also given between brackets. BMD = bone mineral density, ABI = anklebrachial index, NA = not available. GC-MS = gas chromatography -mass spectrometry, CV = coefficient of variation. Spearman Rank correlation coefficients (r S ) are shown, with p values between brackets, for serum estradiol (E2) levels measured by either immunoassay or MS, versus study subject characteristics. Because of multiple testing, the significance threshold was set at p=0.01. hsCRP = high-sensitivity Creactive protein, HDL = high-density lipoprotein, LDL = low-density lipoprotein, ApoA1 = apolipoprotein A1, ApoB = apolipoprotein B. NS = non significant. 
EMAS
SUPPLEMENTAL
